This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Mar 2011

Novavax and VaxInnate Win Flu Vaccine Contracts

Novavax and VaxInnate have received the US Department of Health and Human Service (HHS) contract to develop new types of vaccine and new ways to make flu vaccine.

Clinical-stage biopharmaceutical company Novavax and New Jersey-based VaxInnate have been awarded contract from the US Department of Health and Human Service for the advanced development of seasonal flu vaccines.


Novavax received a $97m contract to develop new vaccines using insect cells to create virus-like particles that stimulate a strong immune response in humans.


VaxInnate was awarded the second contract, worth $117.9m, to develop a recombinant influenza vaccine technology based on combining influenza and bacteria proteins.


The contracts, totally valued at $215m, will run over three years and may be extended for two more, boosting the p

Related News